Previous 10 | Next 10 |
San Francisco, CA - ( NewMediaWire ) - February 16, 2021 - Oncology Pharma, Inc. (OTC: ONPH) is pleased to announce that Dr. Henry Smith has accepted the role of Chairman of the Scientific Advisory Board. Dr. Henry Smith has over 50 years’ experience in Healthcare. Dr. ...
SAN FRANCISCO, CA, Feb. 16, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire – Oncology Pharma, Inc. (OTC: ONPH) is pleased to announce that Dr. Henry Smith has accepted the role of Chairman of the Scientific Advisory Board. Dr. Henry Smith has over 50 years’ experience in He...
Oncology Pharma (ONPH) announces that it has renewed its world-wide licensing agreement with Ribera Solutions with exclusivity for oncology, including drug development, clinical trials, personalized oncology and therapeutics.The licensing agreement, Connect2Med, is a patient engagement and re...
San Francisco, CA - ( NewMediaWire ) - February 09, 2021 - Oncology Pharma Inc. (OTC: ONPH) is pleased to announce that it has renewed its world-wide Licensing Agreement with Ribera Solutions (under its tradename “Connect2Med”) with exclusivity for oncology, including ...
SAN FRANCISCO, CA, Feb. 03, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire – Oncology Pharma, Inc. (OTC: ONPH) is pleased to announce that it has extended its Licensing Agreement with NanoSmart Pharmaceuticals, Inc. for use in Human Oncology. NanoSmart's patented, human-derive...
San Francisco, CA, Jan. 28, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire -- Oncology Pharma Inc. (OTC: ONPH) is pleased to announce that it has retained the services of Mr. James Smith, CPA as its new Chief Financial Officer. Mr. James Smith, CPA is a seasoned executive offic...
San Francisco, CA, Aug. 27, 2020 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- Oncology Pharma, Inc. (OTCPK: ONPH) is pleased to announce that it has extended its Letter of Intent with Kalos Therapeutics. George Malasek was brought into the Company, as Interim CEO, to assist in moving the Comp...
Oncology Pharma Inc. (OTCPK:ONPH) is pleased to announce further information from it's Licensor, Kalos Therapeutics "Kalos" PHOENIX, AZ / ACCESSWIRE / April 21, 2020 / Kalos Therapeutics announced its latest progress in its efforts to discover and develop a novel multi-drug cocktail o...
SAN FRANCISCO, CA, April 06, 2020 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE ‒ Oncology Pharma, Inc. (OTCPK: ONPH) and Kalos Therapeutics (“Kalos”) announced today that the companies amended the terms of their collaboration to explore treatment opportunities of the COVID-19 v...
San Francisco, CA, March 11, 2020 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- Oncology Pharma, Inc. (OTCPK: ONPH) is pleased to announce that it is continuing its relationship with NanoSmart Pharmaceuticals, Inc. and has extended its Licensing Agreement and co-development for both its human onc...
News, Short Squeeze, Breakout and More Instantly...
Oncology Pharma Inc Company Name:
ONPH Stock Symbol:
OTCMKTS Market:
SAN FRANCISCO, CA / ACCESSWIRE / July 12, 2022 / Oncology Pharma Inc. (OTC PINK:ONPH) - Oncology Pharma, Inc. ("The Company") is furthering progress in discussions with investors and developing the financing model towards the next step of the development process with its Nanoemulsion drug de...
SAN FRANCISCO, CA / ACCESSWIRE / June 29, 2022 / Oncology Pharma Inc. (OTC PINK:ONPH) - Oncology Pharma, Inc. ("The Company") is pleased to be reviewing the financing for taking the steps on moving forward with its development process of. the Nanoemulsuion Drug Delivery System. Many antican...
SAN FRANCISCO, CA / ACCESSWIRE / June 8, 2022 / Oncology Pharma Inc. (OTC PINK:ONPH) - Oncology Pharma, Inc. ("The Company") is pleased that the initial feasibility stage is complete and results have met the threshold to move forward. The formulation under development consisted of the activ...